Cargando…
A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
AIMS: The best revascularization strategy for patients with ischaemic heart failure (IHF) remains unclear. Current evidence and guidelines mainly focus on patients with severe ischaemic heart failure (ejection fraction [EF] < 35%). There are limited data comparing clinical outcomes of coronary ar...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065860/ https://www.ncbi.nlm.nih.gov/pubmed/35194977 http://dx.doi.org/10.1002/ehf2.13852 |
_version_ | 1784699681705558016 |
---|---|
author | Wang, Kun Wang, Le Cong, Hongliang Zhang, Jingxia Hu, Yuecheng Zhang, Yingyi Zhang, Rui Li, Wenyu Qi, Wei |
author_facet | Wang, Kun Wang, Le Cong, Hongliang Zhang, Jingxia Hu, Yuecheng Zhang, Yingyi Zhang, Rui Li, Wenyu Qi, Wei |
author_sort | Wang, Kun |
collection | PubMed |
description | AIMS: The best revascularization strategy for patients with ischaemic heart failure (IHF) remains unclear. Current evidence and guidelines mainly focus on patients with severe ischaemic heart failure (ejection fraction [EF] < 35%). There are limited data comparing clinical outcomes of coronary artery bypass grafting (CABG) with implantation of drug‐eluting stents (DESs) in patients with mild to moderate ischaemic heart failure (EF 35–50%). It is therefore unknown whether percutaneous coronary intervention (PCI) with DES implantation can provide comparable outcomes to CABG in these patients. METHODS AND RESULTS: From January 2016 to December 2017, we enrolled patients with mildly to moderately reduced EF (35–50%) who had undergone PCI with DESs or CABG. Patients with a history of CABG, presented with acute ST‐elevation myocardial infarction (MI) or acute heart failure, and patients who had undergone CABG concomitant valvular or aortic surgery were excluded. Propensity score‐matching analysis was performed between the two groups. Kaplan–Meier analysis and multivariate Cox proportional hazard regression were applied to assess all‐cause mortality and individual end points. A total of 2050 patients (1330 PCIs and 720 CABGs) were included, and median follow‐up was 45 months (interquartile range 40 to 54). There were significant differences in all‐cause death between the two groups: 77 patients in the PCI group and 27 in the CABG group (DES vs. CABG: 5.8% vs. 3.8%, P = 0.045). After propensity score matching for the entire population, 601 matched pairs were obtained. The long‐term cumulative rate of all‐cause death was significantly different between the two groups (DES vs. CABG: 5.8% vs. 2.7%, P = 0.006). No differences were found in the rates of cardiac death (DES vs. CABG: 4.8% vs. 3.0%, P = 0.096), recurrent MI (DES vs. CABG: 4.0% vs. 2.8%, P = 0.234), and stroke (DES vs. CABG: 6.8% vs. 5.2%, P = 0.163). The rate of repeat coronary revascularization was significantly higher in the PCI group than in the CABG group (12.1% vs. 6.0%, P = 0.000). CONCLUSIONS: Considering the higher long‐term survival rate and lower repeat‐revascularization rate, CABG may be superior to DES implantation in patients with mildly to moderately reduced EF (35–50%) and significant CAD. |
format | Online Article Text |
id | pubmed-9065860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90658602022-05-04 A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure Wang, Kun Wang, Le Cong, Hongliang Zhang, Jingxia Hu, Yuecheng Zhang, Yingyi Zhang, Rui Li, Wenyu Qi, Wei ESC Heart Fail Original Articles AIMS: The best revascularization strategy for patients with ischaemic heart failure (IHF) remains unclear. Current evidence and guidelines mainly focus on patients with severe ischaemic heart failure (ejection fraction [EF] < 35%). There are limited data comparing clinical outcomes of coronary artery bypass grafting (CABG) with implantation of drug‐eluting stents (DESs) in patients with mild to moderate ischaemic heart failure (EF 35–50%). It is therefore unknown whether percutaneous coronary intervention (PCI) with DES implantation can provide comparable outcomes to CABG in these patients. METHODS AND RESULTS: From January 2016 to December 2017, we enrolled patients with mildly to moderately reduced EF (35–50%) who had undergone PCI with DESs or CABG. Patients with a history of CABG, presented with acute ST‐elevation myocardial infarction (MI) or acute heart failure, and patients who had undergone CABG concomitant valvular or aortic surgery were excluded. Propensity score‐matching analysis was performed between the two groups. Kaplan–Meier analysis and multivariate Cox proportional hazard regression were applied to assess all‐cause mortality and individual end points. A total of 2050 patients (1330 PCIs and 720 CABGs) were included, and median follow‐up was 45 months (interquartile range 40 to 54). There were significant differences in all‐cause death between the two groups: 77 patients in the PCI group and 27 in the CABG group (DES vs. CABG: 5.8% vs. 3.8%, P = 0.045). After propensity score matching for the entire population, 601 matched pairs were obtained. The long‐term cumulative rate of all‐cause death was significantly different between the two groups (DES vs. CABG: 5.8% vs. 2.7%, P = 0.006). No differences were found in the rates of cardiac death (DES vs. CABG: 4.8% vs. 3.0%, P = 0.096), recurrent MI (DES vs. CABG: 4.0% vs. 2.8%, P = 0.234), and stroke (DES vs. CABG: 6.8% vs. 5.2%, P = 0.163). The rate of repeat coronary revascularization was significantly higher in the PCI group than in the CABG group (12.1% vs. 6.0%, P = 0.000). CONCLUSIONS: Considering the higher long‐term survival rate and lower repeat‐revascularization rate, CABG may be superior to DES implantation in patients with mildly to moderately reduced EF (35–50%) and significant CAD. John Wiley and Sons Inc. 2022-02-22 /pmc/articles/PMC9065860/ /pubmed/35194977 http://dx.doi.org/10.1002/ehf2.13852 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Wang, Kun Wang, Le Cong, Hongliang Zhang, Jingxia Hu, Yuecheng Zhang, Yingyi Zhang, Rui Li, Wenyu Qi, Wei A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure |
title | A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure |
title_full | A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure |
title_fullStr | A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure |
title_full_unstemmed | A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure |
title_short | A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure |
title_sort | comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065860/ https://www.ncbi.nlm.nih.gov/pubmed/35194977 http://dx.doi.org/10.1002/ehf2.13852 |
work_keys_str_mv | AT wangkun acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT wangle acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT conghongliang acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT zhangjingxia acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT huyuecheng acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT zhangyingyi acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT zhangrui acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT liwenyu acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT qiwei acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT wangkun comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT wangle comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT conghongliang comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT zhangjingxia comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT huyuecheng comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT zhangyingyi comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT zhangrui comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT liwenyu comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure AT qiwei comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure |